Login to Your Account

Clinic Roundup

Wednesday, November 6, 2013
• Cel-Sci Corp., of Vienna, Va., said a second interim review of the safety data from its open-label, randomized, Phase III study of immunotherapy candidate Multikine (leukocyte interleukin, injection) was conducted, with the independent data monitoring board recommending that the study continue unmodified.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription